Implementation of a Suicide Prevention Gatekeeper Program in the University Setting

The goal of this clinical trial is to assess the effectiveness of a suicide prevention training program (Gatekeepers) tailored to university students in Spain. The main questions it aims to answer are: * Does the training program improve suicide-related knowledge, attitudes, perceived behavioral control, and gatekeeper behaviors among students? * Are there differences in training outcomes by gender, and how do they affect program engagement and effectiveness? Researchers will compare a Immediate Intervention Group (GTK-IG), which will receive the full training immediately, with a 2) the Delayed Intervention Group (GTK-DG), which will be a waitlist control during the first phase of the study, to evaluate the program's short- and medium-term impact, using both in-person and online formats. which will be a waitlist control during the first phase of the study. Participants will: * Be randomly assigned to the intervention or control group, choosing between in-person or online training * Complete online surveys at three timepoints: before the program (T0), immediately after (T1), 2-3 months later (T2), and 9-12 months follow-up (T3). * Attend two 3-hour training sessions covering key suicide prevention competencies * Participate in a follow-up session with focus group discussion to qualitatively assess retention and use of learned skills * Complete validated questionnaires on suicide prevention literacy, attitudes, stigma, and self-reported gatekeeper behaviors This trial includes validation of the Spanish versions of the WISE (Willingness to Intervene Against Suicide Enhanced Questionnaire) and ACT as Gatekeeper measures. The study is registered at ClinicalTrials.gov and follows CONSORT and SPIRIT guidelines. Ethical approval was granted by the Human Research Ethics Committee at the University of Valencia.

NCT Number	NCT07052240
Lead Sponsor	University of Valencia
Conditions	Suicide Prevention, Suicide Awareness, Suicide Behavior
Enrollment	420 participants
Start Date	2025-12-15
Primary Completion	2027-07 (estimated)
Study Completion	2028-08 (estimated)
Updated on ClinicalTrials.gov	2026-01-15